
|Articles|April 30, 2007
FDA denies Lilly appeal
The FDA has denied Eli Lilly's appeal of the agency's ruling requiring it to conduct an additional three-year study of ruboxistaurin mesylate (Arxxant) before it can be approved for treating diabetic retinopathy (DR).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement




















